​Effective June 30, 2023, AmeriHealth HMO, Inc., AmeriHealth Insurance Company of New Jersey, and AmeriHealth Administrators will update their medical policy on belantamab mafodotin-blmf (Blenrep) for Commercial members.

GlaxoSmithKline initiated the process for withdrawal of the BLA for this biologic at the request of the U.S. Food and Drug Administration (FDA). Blenrep was granted accelerated approval on August 5, 2020, based on the primary endpoint of overall response rate (ORR) from the DREAMM-2 study, with full approval contingent upon confirmed clinical benefit from the DREAMM-3 randomized Phase 3 trial. However, this confirmatory trial did not meet its primary endpoint of superior progression-free survival (PFS).

The HCPCS code J9037 will be included in the following medical policy with Not Medically Necessary coverage effective July 1, 2023: #00.01.24j: Not Medically Necessary Services (Medical Therapies and Pharmaceutical Products) and Obsolete or Unreliable Diagnostic Tests.

For more information, please view #08.01.70b: Belantamab mafodotin-blmf (Blenrep), which was published as a notification on May 31, 2023.